Innovent Reports First Patient Dosing in the P-III (GLORY-2) Trial of Mazdutide (IBI362) in Chinese Adults with Obesity
Shots:
- The company has administered first patient with mazdutide’s 9mg (HD), in the P-III (GLORY-2) study for the treatment of Chinese adults with obesity
- The P-III (GLORY-2) trial investigates mazdutide (9mg) vs PBO in 450 patients to find the percentage change in body weight and the proportion of individuals with 5% or higher body weight loss from baseline at 60 wks.
- The P-III study follows a P-II trial in Chinese patients with obesity (BMI ≥ 30 kg/m2) in which mazdutide (9mg) showed an 18.6% PBO-adjusted mean percent reduction in body weight after 48wks. & decrease in waist circumference, blood pressure, lipids, serum uric acid, transaminase, and liver fat, offering multiple metabolic benefits
Ref: Innovent | Image: Innovent
Related News:- Innovent Announces the Results of P-II Study for Mazdutide (IBI362) in Chinese Patients with Overweight or Obesity
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
